Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis.

2.50
Hdl Handle:
http://hdl.handle.net/10541/67987
Title:
Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis.
Authors:
Donne, A J; Rothera, M P; Homer, Jarrod J
Abstract:
OBJECTIVE: Cidofovir is the most contemporary adjuvant treatment for recurrent respiratory papillomatosis (RRP) and its use is increasing. Cidofovir is potentially harmful. Otolaryngologists should understand the science of cidofovir and review the current published data on the effects of this therapy. METHOD: Pubmed was searched using the terms cidofovir and papillomatosis. Comparisons were made between published articles. RESULTS: Thirteen articles were identified between 1998 and 2006, representing the treatment of 142 patients. Cidofovir did result in a significant improvement of papillomatous lesions in the majority (60%) of patients despite the use of different regimes of cidofovir administration. There was no unifying protocol in use. A partial response was demonstrated in 29% of patients. 7.5% had no response however, an additional 3.5% patients were lost to follow-up. No malignant change was reported. CONCLUSION: Cidofovir does appear to be effective in improving the outcome of patients with RRP. There are no reports of malignant transformation despite concerns raised by toxicology studies.
Affiliation:
University Department of Otolaryngology and Head and Neck Surgery, Manchester Royal Infirmary, UK. ajdonne@doctors.org.uk
Citation:
Scientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis. 2008, 72 (7):939-44 Int. J. Pediatr. Otorhinolaryngol.
Journal:
International Journal of Pediatric Otorhinolaryngology
Issue Date:
Jul-2008
URI:
http://hdl.handle.net/10541/67987
DOI:
10.1016/j.ijporl.2008.04.003
PubMed ID:
18502519
Type:
Article
Language:
en
ISSN:
0165-5876
Appears in Collections:
All Christie Publications ; Surgery

Full metadata record

DC FieldValue Language
dc.contributor.authorDonne, A J-
dc.contributor.authorRothera, M P-
dc.contributor.authorHomer, Jarrod J-
dc.date.accessioned2009-05-12T18:08:58Z-
dc.date.available2009-05-12T18:08:58Z-
dc.date.issued2008-07-
dc.identifier.citationScientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis. 2008, 72 (7):939-44 Int. J. Pediatr. Otorhinolaryngol.en
dc.identifier.issn0165-5876-
dc.identifier.pmid18502519-
dc.identifier.doi10.1016/j.ijporl.2008.04.003-
dc.identifier.urihttp://hdl.handle.net/10541/67987-
dc.description.abstractOBJECTIVE: Cidofovir is the most contemporary adjuvant treatment for recurrent respiratory papillomatosis (RRP) and its use is increasing. Cidofovir is potentially harmful. Otolaryngologists should understand the science of cidofovir and review the current published data on the effects of this therapy. METHOD: Pubmed was searched using the terms cidofovir and papillomatosis. Comparisons were made between published articles. RESULTS: Thirteen articles were identified between 1998 and 2006, representing the treatment of 142 patients. Cidofovir did result in a significant improvement of papillomatous lesions in the majority (60%) of patients despite the use of different regimes of cidofovir administration. There was no unifying protocol in use. A partial response was demonstrated in 29% of patients. 7.5% had no response however, an additional 3.5% patients were lost to follow-up. No malignant change was reported. CONCLUSION: Cidofovir does appear to be effective in improving the outcome of patients with RRP. There are no reports of malignant transformation despite concerns raised by toxicology studies.en
dc.language.isoenen
dc.subjectCancer Recurrenceen
dc.subjectThoracic Canceren
dc.subjectCidofoviren
dc.subject.meshAntiviral Agents-
dc.subject.meshCytosine-
dc.subject.meshHumans-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshPapilloma-
dc.subject.meshPapillomavirus Infections-
dc.subject.meshPhosphonic Acids-
dc.subject.meshRespiratory Tract Neoplasms-
dc.titleScientific and clinical aspects of the use of cidofovir in recurrent respiratory papillomatosis.en
dc.typeArticleen
dc.contributor.departmentUniversity Department of Otolaryngology and Head and Neck Surgery, Manchester Royal Infirmary, UK. ajdonne@doctors.org.uken
dc.identifier.journalInternational Journal of Pediatric Otorhinolaryngologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.